TR200904500A2 - Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. - Google Patents
Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.Info
- Publication number
- TR200904500A2 TR200904500A2 TR2009/04500A TR200904500A TR200904500A2 TR 200904500 A2 TR200904500 A2 TR 200904500A2 TR 2009/04500 A TR2009/04500 A TR 2009/04500A TR 200904500 A TR200904500 A TR 200904500A TR 200904500 A2 TR200904500 A2 TR 200904500A2
- Authority
- TR
- Turkey
- Prior art keywords
- ezetimibe
- nanocrystals
- preparation
- methods
- pharmaceutical formulations
- Prior art date
Links
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 title abstract 3
- 229960000815 ezetimibe Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000002159 nanocrystal Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2009/04500A TR200904500A2 (tr) | 2009-06-10 | 2009-06-10 | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
| PCT/TR2010/000106 WO2010144066A1 (fr) | 2009-06-10 | 2010-06-04 | Procédé pour la préparation de nano-cristaux d'ézétimibe |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2009/04500A TR200904500A2 (tr) | 2009-06-10 | 2009-06-10 | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200904500A2 true TR200904500A2 (tr) | 2009-10-21 |
Family
ID=42740287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2009/04500A TR200904500A2 (tr) | 2009-06-10 | 2009-06-10 | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR200904500A2 (fr) |
| WO (1) | WO2010144066A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9388440B2 (en) | 2009-04-01 | 2016-07-12 | Mylan Laboratories Limited | Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe |
| EP2700632A4 (fr) * | 2011-04-18 | 2014-09-03 | Hefei Beini Medical Technology Company Ltd | Procédé de purification de bloquants du canal calcique de type dihydropyridine et préparation de nanoparticules de ceux-ci |
| CN103655481A (zh) * | 2012-09-18 | 2014-03-26 | 江苏柯菲平医药有限公司 | 一种依折麦布口服制剂制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
| US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US20020115696A1 (en) | 1999-06-18 | 2002-08-22 | Yoel Kloog | Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists |
| US20040115134A1 (en) | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
| ES2290562T3 (es) | 2001-01-26 | 2008-02-16 | Schering Corporation | Combinaciones del activador del receptor activado por el proliferador de los peroxisomas (ppar) fenofibrato con el inhibidor de la absorcion de esteroles ezetimiba para indicaciones vasculares. |
| DE60319073T2 (de) | 2002-03-20 | 2009-02-05 | Elan Pharma International Ltd. | Nanopartikelzusammensetzungen von mitogen-aktivierten protein (map) kinase inhibitoren |
| US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| EP1531799A1 (fr) | 2002-06-10 | 2005-05-25 | Elan Pharma International Limited | Formulations nanoparticulaires comprenant des derives d'un inhibiteur de la hmg coa-reductase ("statines"), nouvelles combinaisons associees et production de ces compositions pharmaceutiques |
| WO2004060351A2 (fr) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Formulation pharmaceutique ayant un agent actif insoluble |
| WO2006002140A2 (fr) | 2004-06-21 | 2006-01-05 | Nektar Therapeutics | Compositions renfermant de l'amphotericine b, procedes et systemes correspondants |
| EP1817280A1 (fr) * | 2004-12-03 | 2007-08-15 | Teva Pharmaceutical Industries Ltd. | Polymorphes de l'ezetimibe |
| JP5080445B2 (ja) * | 2005-04-13 | 2012-11-21 | アボット ゲーエムベーハー ウント コー． カーゲー | 超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用 |
| US20060234996A1 (en) | 2005-04-14 | 2006-10-19 | Itai Adin | Novel crystalline form of ezetimibe and processes for the preparation thereof |
| US20120128728A1 (en) | 2005-12-28 | 2012-05-24 | Novartis Pharma Ag | Compositions Comprising Amphotericin B |
| CA2644905A1 (fr) | 2006-03-06 | 2007-09-13 | Teva Pharmaceutical Industries Ltd. | Compositions a base d'ezetimibe |
| US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
| CN101679236B (zh) | 2007-01-24 | 2013-03-06 | 克尔克公司 | 依泽替米贝的制备方法和其的衍生物 |
| US10189957B2 (en) * | 2007-01-26 | 2019-01-29 | Isp Investments Llc | Formulation process method to produce spray dried products |
| EP2120882A2 (fr) | 2007-02-23 | 2009-11-25 | Krka | Composition pharmaceutique comprenant un inhibiteur d'absorption du cholestérol |
| AU2008281640A1 (en) * | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
-
2009
- 2009-06-10 TR TR2009/04500A patent/TR200904500A2/xx unknown
-
2010
- 2010-06-04 WO PCT/TR2010/000106 patent/WO2010144066A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010144066A1 (fr) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| EA201390203A1 (ru) | Способы получения тубулизинов | |
| UA111717C2 (uk) | Склад для перорального введення і ліпофільні солі метилналтрексону | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| MX361218B (es) | Análogos de spliceostatina. | |
| EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
| AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
| EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
| EA201170753A1 (ru) | Налмефена гидрохлорид дигидрат | |
| MX361413B (es) | Formas cristalinas de un macrólido y usos para las mismas. | |
| CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
| MY187718A (en) | Pharmaceutical formulations | |
| EA201300034A1 (ru) | Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения | |
| EA201291050A1 (ru) | Комбинация лекарств с протеинсвязывающими пролекарствами | |
| EA201291211A1 (ru) | Фармацевтические композиции, содержащие гидроморфон и налоксон | |
| BR112014002845A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| CR20120146A (es) | Derivados de espirolactama y usos de los mismos | |
| UA118562C2 (uk) | Модулятори рецептора cxcr7 | |
| EA201400444A1 (ru) | Производные 2-оксопиперидинила | |
| TR200904500A2 (tr) | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. | |
| EA201791354A3 (ru) | Препараты производных пиримидиндиона |